The down-regulation of HER2 enhanced the sensitivity to taxol, gefitinib and trastuzumab (Figure 13A), increased caspase-3 activity (Figure 13B) and PARP cleavage (Figure 13C) in response to these anti-cancer drugs. This evidence concerns the gene CASP3 and cancer.